Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Risk Assessment

View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Bristol-Myers Squibb Co is: High Risk: Good fundamentals, beware of shrinking business.

Competitive Comparison of Bristol-Myers Squibb Co's Risk Assessment

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bristol-Myers Squibb Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Risk Assessment falls into.

Bristol-Myers Squibb Co (NYSE:BMY) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Bristol-Myers Squibb Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Executives

Christopher S. Boerner	officer: EVP, Chief Commercial Officer	21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii	director	1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman	officer: EVP, Corporate Affairs	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge	officer: SVP, Human Resources	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge	officer: EVP, Chief Research Officer	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey	officer: Pres., Research & Early Dev.	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky	officer: EVP, Chief Commercial Officer	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio	officer: EVP & Chief Commercial Officer	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins	officer: EVP, Chief Financial Officer	C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt	director	BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung	officer: Vice President and Secretary	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees	officer: SVP & Controller	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan	officer: EVP, Glob. Prod. Dev. & Supply	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers	officer: EVP, Chief Digital & Tech Off.	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von	officer: SVP, Enterp. Services & CIO	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543